Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Sanara Medtech Applied Technologies LLC currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, which indicates that different individuals are reviewing the company's active applications. This provides multiple perspectives even within a small portfolio of 2 pending matters.
The 2 distinct examiners are located in 2 distinct art units. This distribution shows that the company's applications are being reviewed in different specialized sections of the patent office. Even with a small number of 2 pending actions, the portfolio is spread across multiple administrative units rather than being concentrated in a single art unit.
MI, QIUWEN is the busiest examiner for this portfolio with 1 busiest examiner pending action. Since there are 2 pending office actions in total and 2 distinct examiners, the workload is distributed evenly. MI, QIUWEN is responsible for one of the 2 actions, representing one part of the current prosecution activity for the company.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MI, QIUWEN | 1 | 68.4% | +49.9% |
| NGUYEN, JOHN P | 1 | 43.9% | +41.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18128858 | TISSUE REPAIR AND WOUND HEALING COMPOSITION AND METHOD USING LOW MOLECULAR WEIGHT HYDROLYZED COLLAGEN | MI, QIUWEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18128866 | WOUND HEALING AND TISSUE REPAIR COMPOSITION AND METHOD USING LOW MOLECULAR WEIGHT COLLAGEN AND BIOACTIVE GLASS | NGUYEN, JOHN P | 43d overdue |
| 18128858 | TISSUE REPAIR AND WOUND HEALING COMPOSITION AND METHOD USING LOW MOLECULAR WEIGHT HYDROLYZED COLLAGEN | MI, QIUWEN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18128858 | TISSUE REPAIR AND WOUND HEALING COMPOSITION AND METHOD USING LOW MOLECULAR WEIGHT HYDROLYZED COLLAGEN | MI, QIUWEN | 1655 | §102§103 | Non-Final OA | — | Pending | Mar 30, 2023 |
| 18128866 | WOUND HEALING AND TISSUE REPAIR COMPOSITION AND METHOD USING LOW MOLECULAR WEIGHT COLLAGEN AND BIOACTIVE GLASS | NGUYEN, JOHN P | 1619 | §103 | Non-Final OA | 43d overdue | Pending | Mar 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial